Focal Radiation Enhances Paclitaxel Therapy in a Mouse Model of Triple Negative Breast Cancer

AACR 2017 -- Triple negative breast cancer (TNBC) accounts for 15-20% of all breast cancers in the United States. Patients with TNBC have poorer prognosis and therapeutic intervention is more challenging due to insensitivity to hormonal and anti-HER2 therapies. Therapeutic options for TNBC can include chemotherapy and/or radiation (RT) treatment.